IMMNOV — Immunovia AB (publ) Share Price
0.000.00%
Last trade - 00:00- SEK79.43m
- SEK12.91m
- SEK1.58m
- 11
- 10
- 60
- 15
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.19 | ||
| Price to Tang. Book | 1.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 50.43 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -431.04% | ||
| Return on Equity | -199.13% | ||
| Operating Margin | -18822.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 0.36 | 0.36 | 0.84 | 1.15 | 1.57 | 622 | n/a | 36.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Directors
- Carl Borrebaeck NEC (73)
- Patrik Dahlen CEO (59)
- Karin Liwendahl CFO
- Hans Liljenborg FID (61)
- Lotta Blomgren COO (59)
- Michael Pettigrew SVP
- Rolf Ehrnstrom CSO (66)
- Linda Mellby VRD (40)
- Hans Pedersen VBD
- Laura Chirica DSL (52)
- Annika Andersson OTH
- Mats Grahn DRC (58)
- Martin Moller DRC
- Peter Andersen IND (65)
- Mimmi Ekberg IND (60)
- Hans Johansson IND (65)
- Christofer Sjogren IND (54)
- Ann-Christine Sundell IND (56)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 24th, 2007
- Public Since
- December 1st, 2015
- No. of Employees
- 11
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 45,287,498
- Address
- Medicon Village, Scheelevagen 8, LUND, 223 63
- Web
- https://immunovia.com/
- Phone
- +46 462756000
- Contact
- Karin Liwendahl
- Auditors
- HLB Auditoriet AB
Upcoming Events for IMMNOV
Immunovia AB (publ) Annual Shareholders Meeting
Immunovia AB (publ) Annual Shareholders Meeting
Q2 2024 Immunovia AB (publ) Earnings Release
Similar to IMMNOV
Acarix AB
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
Aegirbio AB
OMX Nordic Exchange Stockholm
Arcoma AB
OMX Nordic Exchange Stockholm
FAQ
What is the Immunovia AB (publ) share price?
As of Today at 19:11 UTC, shares in Immunovia AB (publ) are trading at SEK1.75. This share price information is delayed by 15 minutes.
How has the Immunovia AB (publ) share price performed this year?
Shares in Immunovia AB (publ) last closed at SEK1.75 and the price had moved by -60.72% over the past 365 days. In terms of relative price strength the Immunovia AB (publ) share price has underperformed the FTSE Global All Cap Index by -63.12% over the past year.
What are the analyst and broker recommendations for Immunovia AB (publ)?
The overall consensus recommendation for Immunovia AB (publ) is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Immunovia AB (publ) dividend yield?
Immunovia AB (publ) does not currently pay a dividend.
Does Immunovia AB (publ) pay a dividend?
Immunovia AB (publ) does not currently pay a dividend.
When does Immunovia AB (publ) next pay dividends?
Immunovia AB (publ) does not currently pay a dividend.
How do I buy Immunovia AB (publ) shares?
To buy shares in Immunovia AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Immunovia AB (publ)?
As of the previous close price of SEK1.75, shares in Immunovia AB (publ) had a market capitalisation of SEK79.43m.
Where are Immunovia AB (publ) shares listed?
Here are the trading details for Immunovia AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: IMMNOV
What kind of share is Immunovia AB (publ)?
Based on an overall assessment of its quality, value and momentum Immunovia AB (publ) is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Immunovia AB (publ) share price forecast for 2024?
The analyst consensus target price for shares in Immunovia AB (publ) is SEK102.09. That is 5720.41% above the last closing price of SEK1.75.
Analysts covering Immunovia AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of SEK7.00 for the next financial year.
What is the trend in the Immunovia AB (publ) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immunovia AB (publ). Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +152.6%.
As of the last closing price of SEK1.75, shares in Immunovia AB (publ) were trading +21.6% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Immunovia AB (publ) PE Ratio?
The Immunovia AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK1.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Immunovia AB (publ)?
Immunovia AB (publ)'s management team is headed by:
- Carl Borrebaeck - NEC
- Patrik Dahlen - CEO
- Karin Liwendahl - CFO
- Hans Liljenborg - FID
- Lotta Blomgren - COO
- Michael Pettigrew - SVP
- Rolf Ehrnstrom - CSO
- Linda Mellby - VRD
- Hans Pedersen - VBD
- Laura Chirica - DSL
- Annika Andersson - OTH
- Mats Grahn - DRC
- Martin Moller - DRC
- Peter Andersen - IND
- Mimmi Ekberg - IND
- Hans Johansson - IND
- Christofer Sjogren - IND
- Ann-Christine Sundell - IND